EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medigene AG's enterprise value is €22.24 Mil.
Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-14.58 Mil. Therefore, Medigene AG's EV-to-EBITDA for today is -1.52.
The historical rank and industry rank for Medigene AG's EV-to-EBITDA or its related term are showing as below:
XTER:MDG1'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.18 Med: -5.44 Max: 2
Current: -1.52
During the past 13 years, the highest EV-to-EBITDA of Medigene AG was 2.00. The lowest was -43.18. And the median was -5.44.
XTER:MDG1's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.67
vs XTER:MDG1: -1.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Medigene AG EV-to-EBITDA Historical Data
The historical data trend for Medigene AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medigene AG's EV-to-EBITDA
For the Biotechnology subindustry, Medigene AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigene AG's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigene AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medigene AG's EV-to-EBITDA falls into.
Medigene AG EV-to-EBITDA Calculation
Medigene AG's EV-to-EBITDA for today is calculated as:
Medigene AG's current Enterprise Value is €22.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-14.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigene AG (XTER:MDG1) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Medigene AG's PE Ratio for today is calculated as:
Medigene AG's share price for today is €1.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.627.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Medigene AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:MDG1 has been successfully added to your 